INTRODUCTION AND OBJECTIVES: MIBC patients who respond to cisplatin based NAC, defined as stage <ypT2 at cystectomy, exhibit a high 5 year cancer specific survival (CSS) of up to 90%. In contrast, non-responders (stage ¼ypT2 at cystectomy) exhibit a worse CSS (30-40%) than cystectomy alone, highlighting the need for predictors of NAC response. Recent MIBC studies have identified a gene expression based taxonomy (basal versus luminal phenotypes) similar to that of breast cancer. We evaluated the role of such a classification using immunohistochemical stains in a NAC cohort of MIBC.
INTRODUCTION AND OBJECTIVES: MIBC patients who respond to cisplatin based NAC, defined as stage <ypT2 at cystectomy, exhibit a high 5 year cancer specific survival (CSS) of up to 90%. In contrast, non-responders (stage ¼ypT2 at cystectomy) exhibit a worse CSS (30-40%) than cystectomy alone, highlighting the need for predictors of NAC response. Recent MIBC studies have identified a gene expression based taxonomy (basal versus luminal phenotypes) similar to that of breast cancer. We evaluated the role of such a classification using immunohistochemical stains in a NAC cohort of MIBC.
METHODS: Pre-treatment tissues from a cohort of 71 NAC treated MIBC patients at our institution between 2000 and 2013 were incorporated in tissue microarray and stained for CK5/6 and GATA3 (Ventana Medical Systems, AZ). Cases were assigned as luminal or basal phenotype based on the extent (70% cut off) of tumor cells with ¼2+ staining intensity, Figure 1A . We limited our analysis of CSS to the 40 patient who were able to tolerate ¼2 doses of NAC to avoid the confounding effect of patients who were not adequately dosed.
RESULTS: As expected, there was an inverse association for CK5/6 and GATA3: 77% (43/56) of strong GATA3 cases exhibited weak/negative CK5/6 staining, most consistent with the luminal phenotype, and 73% (11/15) of the GATA3 weak/negative cases exhibited strong CK5/6, most consistent with the basal phenotype (Fisher's exact p-value 0.0003). Interestingly there was a~2 fold enrichment of basal the phenotype in cases with residual MIBC following NAC, Figure 1B .
CONCLUSIONS: Our results suggest a differential responsiveness to NAC for MIBC based on assignment of basal and luminal phenotypes. The current findings should be further evaluated taking P53 gene expression status into account, given previous suggestion of chemotherapy resistance in P53 intact (p53-Like) MIBC. Furthermore, comparison to IHC luminal/basal MIBC phenotypes in our cohort of cystectomy only treated patients is ongoing to help discern the prognostic vs predictive role of this classification for NAC. 
Source of

INTRODUCTION AND OBJECTIVES:
It has been reported that lymph node density is superior to TNM nodal status in predicting oncologic outcome after radical cystectomy (RC) for urothelial carcinoma of bladder (UCB). The survival benefits of adjuvant chemotherapy (AC) following RC according to LND were assessed in this study.
METHODS: Of 888 consecutive UCB patients undergoing RC with pelvic lymph node dissection (PLND), 164 (18.5%) received the AC. After controlling preoperative and postoperative clinical and pathological variables, recurrence-free (RFS) and cancer-specific survival (RFS) after RC with PLND were compared between the AC and non AC groups.
RESULTS: After the strict propensity scored matching (both discard, caliper¼0.1), 130 patients with AC were not significantly different with 130 matched patients without AC, in age (62.5 vs. 61.8 years), pT stage (pT3, 78.5 vs. 77.7%), pN stage (pN1, 23.8 vs. 30.8% ;pN2, 32.3 vs. 32.3%), tumor grade (high, 95.4 vs. 87.7%), carcinoma in situ (23.1 vs. 28.5%), lymphovascular invasion (62.3 vs. 58.5%), positive surgical margin (10.0 vs. 10.0%), dissected LN number (19.8 vs. 22.4), and LN density (0.14 vs. 0.15; p range, 0.071-1.000). During median 43.0 months follow-up after the RC with PLND, median RFS of AC group was similar to that of non AC group (37.0 vs. 30.0 months, p¼0.612). CSS were not also different between two groups (60.0 vs. 55.0 months, p¼0.313). However, better RFS (20.0 vs. 9.0 months, p¼0.008) and CSS (44.0 vs. 18.0 months, p¼0.009) of AC group were observed in subgroup of patients with LND 0.05 (N¼122). CONCLUSIONS: After adjusting the possible confounders and selection biases, AC demonstrated better oncological outcomes in patients with LND 0.05. Patients with LND 0.05 on final pathology should be considered the AC for better survival outcomes. 197, No. 4S, Supplement, Sunday, May 14, 2017 especially after neoadjuvant chemotherapy (NAC). We hypothesized that use of adjuvant chemotherapy (AC) is associated with improved survival compared to observation along among patients with advanced disease at RC after NAC. METHODS: Using the National Cancer Database, we identified patients who received NAC prior to RC and had advanced stage (pT3/4) or pathologically involved nodes (pN+) at the time of surgery from 2004-2013. We determined whether patients then received AC or were managed with observation only and used multivariable proportional hazards regression to estimate the impact of AC on overall survival.
RESULTS: Overall 34% (N¼723) of patients who received NAC and underwent RC were pT3/4 and/or pN+. Of these patients, 24% (N¼170) received subsequent chemotherapy and the rest were observed. Median survival for the entire cohort was 21 months . Compared to the observation group, the AC group had longer median survival however this was not statistically significant (23 months [IQR 14-46] versus 20 months [IQR 12-46], log-rank p ¼ 0.52). On multivariate analysis there was no survival advantage for the AC cohort. Subgroup analysis of pN+ patients who received AC showed also did not show a survival advantage.
CONCLUSIONS: Patients who are pT3/4 and/or pN+ after NAC and RC have a poor prognosis. The addition of AC does not seem to be beneficial. Further research should focus identifying patients who may benefit from additional chemotherapy.
Source of Funding: none
MP58-08 THE B4GALT1 EXPRESSION IS PROGNOSTIC AND PREDICTIVE FOR POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFIT IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
Huyang Xie*, Yu Zhu, Zewei Wang, Qiang Fu, Jiejie Xu, Dingwei Ye, Shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: Beta-1, 4-Galactosyltransferase gene (B4GALT) family consists of seven members, which encode corresponding enzymes known as type II membrane-bound glycoproteins. These enzymes catalyze the biosynthesis of different glycoconjugates and saccharide structures, and have been recognized to be involved in various diseases. In this study, we sought to determine the bladder cancer cell's B4GALT1 expression and its association with the infiltrated CD8+ T cell number, together with the association with the patients' outcome, as well as the benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC).
METHODS:
We recruited 201 and 172 patients consecutively with bladder cancer treated by radical cystectomy from 2008 to 2012 in Shanghai Zhongshan Hospital and Fudan University Shanghai Cancer Center (FUSCC), respectively. The first cohort with 201 patients was treated as training set and the other as validation set. TMAs were created in triplicated from formalin-fixed, paraffin embedded specimens. Immunohistochemistry was performed to assess the expression of B4GALT1 in tumor cores and CD8 in both tumor and peri-tumor cores, and its association between B4GALT1 and the infiltrated CD8+ T cell number, also with clinical outcomes.
RESULTS: B4GALT1 expression was significantly associated with tumor size (P¼0.005 and P¼0.014, respectively), T stage (P¼0.017 and P¼0.004, respectively), OS (P<0.001 and P<0.001, respectively) and PFS (P¼0.033 and P¼0.034, respectively) in both cohorts. Furthermore, high expression of B4GALT1 was an independent indicator of poor OS (P¼0.022 and P¼0.017, respectively) in patients with MIBC. The prognostic model containing B4GALT1 showed a better predictive accuracy than the basic models. And the B4GALT1 expression was inverse correlated with the number of peri-tumor infiltrated CD8+ T cell, but not with the number of tumor infiltrated CD8+ T cell. Most importantly, the benefit of adjuvant chemotherapy observed in non-organ confined bladder cancer patients with low B4GALT1 expression was superior to patients with high expression.
CONCLUSIONS: Our study suggested that B4GALT1 is a potential prognostic biomarker of MIBC, and might be a predictive marker for the patients' selection of adjuvant chemotherapy in high recurrence risk subgroup patients. METHODS: We focused on 1112 patients treated with RC and pelvic lymph node dissection, between 1990 and 2012, at a single tertiary referral center. LF was defined as imaging evidence of recurrence in the pelvic soft tissues or nodes below the aortic bifurcation before or within 3 months of detection of distant metastases. Kaplan-Meier log-rank, univariable and multivariable competing risk analyses tested the relationship between clinical and pathological factors and the risk to develop LF during follow up period. Regression tree analysis stratified patients into risk-groups based on their tumor characteristics and the corresponding LF rate.
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RESULTS: Of the 1,122 individuals included in the study, 50 (4.5%) developed LF during follow up period. Median (IQR) follow-up was 62 (35-92) months. At univariable competing risk regression, pathological T stage pT4 vs. pT3 (Hazard Ratio [HR]: 2.55, p¼0.003), positive soft tissue surgical margin (STSM) vs. negative (HR: 2.95, p¼0.005) and non-pure transitional vs. pure transitional histology (HR: 1.79, p¼0.03) were associated with an increased risk of developing LF. On the basis of these variables, the cohort was stratified into four risk
